BridgeMD
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
EU CTIS ID: 2025-524679-22-00
What this study is testing
We aim to systematically assess the effects of up-titration of glimepiride on continuous glucose monitoring (CGM) metrics in individuals diagnosed with HNF1A- or HNF4A-MODY including those who have previously been treated as individuals with T1D or T2D.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- HbA1c ≥48 mmol/mol and/or current insulin treatment
- Age ≥18 years
- Diabetes caused by a heterozygous mutation (pathogenic or likely pathogenic according to ACMG criteria) in the HNF1A-gene or HNF4A-gene
- Informed consent
You likely can't join if
- Breastfeeding, pregnancy or inadequate contraceptive methods in women with childbearing potential
- Nephropathy (eGFR <30 ml/min/1.73 m2 and/or persistent severely increased albuminuria (urine-albumin-creatinine ratio >300 mg/g))
- End-stage liver disease
- Contraindications for use of specific CGM device (e.g. non-manageable skin reactions, use of substances interfering with measurements etc.)
- Known allergic reaction to study drug (glimepiride or other sulphonamides)
- Treatment with SU or glinides within the last 30 days
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.